Alzheimer's disease (AD) is a devastating cause of memory loss and cognitive decline, for which no curative treatment is available.

Until the end of March, Novo Nordisk will let people with prescriptions buy the first two doses of the drugs for $199 a month ...

Novo Nordisk A/S faces intensifying GLP-1 competition, notably from Eli Lilly, prompting price cuts for Wegovy. Learn more ...

Signs of a weight loss price war appeared to worry investors early Monday, and Lilly and Novo stocks were down.

Novo Nordisk is chopping prices again for its popular obesity treatment Wegovy, but doctors say the expense will remain ...

Novo Nordisk said on Monday it would lower the U.S. price of its injectable Wegovy obesity drug and pledged to go "all in" on ...

Novo Holdings A/S, a vehicle for the Novo Nordisk Foundation, is set to exit its remaining position in medical technology ...

Novo Nordisk's new chair Lars Sorensen plans to add pharma expertise and address governance concerns after a major board overhaul backed by the company's foundation.

The cash price for popular weight-loss medication Wegovy is dropping by 30% in U.S. on Monday, according to Novo Nordisk.

Newly-elected chairman of Wegovy-maker Novo Nordisk , Lars Rebien Sorensen, said on Friday he plans to enhance the board's ...

Lars Rebien Sorensenis back as chairman of Novo Nordisk A/S following a shareholder meeting that exposed the depth of rivalry between the Danish drugmaker and US arch nemesis Pfizer Inc.

Novo Nordisk ( ($NVO) ) has provided an update. On November 14, 2025, Novo Nordisk A/S held an Extraordinary General Meeting to elect new members ...